GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Total Receivables

LakeShore Biopharma Co (LakeShore Biopharma Co) Total Receivables : $58.84 Mil (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Total Receivables?

LakeShore Biopharma Co's Total Receivables for the quarter that ended in Sep. 2023 was $58.84 Mil.


LakeShore Biopharma Co Total Receivables Historical Data

The historical data trend for LakeShore Biopharma Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Total Receivables Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Total Receivables
38.11 48.63 67.20

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Receivables Get a 7-Day Free Trial - 48.63 67.36 67.20 58.84

LakeShore Biopharma Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


LakeShore Biopharma Co Total Receivables Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.